The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
RaQualia’s Acid Reducer Now Available in 5 Latin American Countries
RaQualia Pharma said on December 12 that its acid reducer tegoprazan was launched in five Latin American countries through Mexican sublicensing partner Carnot. With this, the drug is now available in a total of 15 nations worldwide.The five markets added…
To read the full story
Related Article
- RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
December 15, 2025
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- RaQualia’s Acid Reducer Tegoprazan Approved in Malaysia
September 27, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Colombia
September 3, 2024
BUSINESS
- Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026
- Takeda Files Polycythemia Vera Drug Rusfertide in US
January 7, 2026
- Daito Snags China Approval for Iguratimod, Its Third In-House Product
January 7, 2026
- China Accepts BLA for Leqembi Subcutaneous Autoinjector: Eisai
January 7, 2026
- Kyorin Licenses Lasvic to UAE’s Lunatus for Middle East Markets
January 6, 2026
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…